A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease

A Phase 2, Multi-Center, Double-Blinded, Placebo-Controlled Safety And Efficacy Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease

The purpose of this study is to demonstrate the safety and efficacy of PF-01913539 in the treatment of patients with mild-to-moderate Alzheimer's Disease. It is a 6-month study enrolling 651 patients in Japan, Hong Kong, Korea, and Republic of China. All patients completing the 6-month study will be eligible to receive PF-01913539 in an open-label extension trial (B1451031).

Inclusion Criteria:

• Mild-to-Moderate Alzheimer's disease
• MMSE score 10-24 inclusive

Exclusion Criteria:

• Administration of anti-dementia drugs including cholinesterase-inhibitors or NMDA receptor antagonists within 90 days
• Complication of other causes of dementia